Literature DB >> 29318508

Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules.

Sara Mariotto1, Sergio Ferrari1, Salvatore Monaco2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29318508     DOI: 10.1007/s11060-018-2743-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  5 in total

1.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Authors:  Anas Younes; Nancy L Bartlett; John P Leonard; Dana A Kennedy; Carmel M Lynch; Eric L Sievers; Andres Forero-Torres
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.

Authors:  Zachary A Corbin; Annie Nguyen-Lin; Shufeng Li; Ziba Rahbar; Mahkam Tavallaee; Hannes Vogel; Katrin A Salva; Gary S Wood; Youn H Kim; Seema Nagpal
Journal:  J Neurooncol       Date:  2017-03-07       Impact factor: 4.130

3.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

Authors:  H Miles Prince; Youn H Kim; Steven M Horwitz; Reinhard Dummer; Julia Scarisbrick; Pietro Quaglino; Pier Luigi Zinzani; Pascal Wolter; Jose A Sanches; Pablo L Ortiz-Romero; Oleg E Akilov; Larisa Geskin; Judith Trotman; Kerry Taylor; Stephane Dalle; Michael Weichenthal; Jan Walewski; David Fisher; Brigitte Dréno; Rudolf Stadler; Tatyana Feldman; Timothy M Kuzel; Yinghui Wang; Maria Corinna Palanca-Wessels; Erin Zagadailov; William L Trepicchio; Wenwen Zhang; Hui-Min Lin; Yi Liu; Dirk Huebner; Meredith Little; Sean Whittaker; Madeleine Duvic
Journal:  Lancet       Date:  2017-06-07       Impact factor: 79.321

4.  Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

Authors:  Daniel J Lewis; Rakhshandra Talpur; Auris O Huen; Michael T Tetzlaff; Madeleine Duvic
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

5.  Brentuximab vedotin: axonal microtubule's Apollyon.

Authors:  S Mariotto; S Ferrari; M Sorio; F Benedetti; G Tridente; T Cavallaro; A Gajofatto; S Monaco
Journal:  Blood Cancer J       Date:  2015-08-28       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.